Compare XERS & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XERS | INSP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2021 | 2018 |
| Metric | XERS | INSP |
|---|---|---|
| Price | $8.85 | $57.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | $10.83 | ★ $94.00 |
| AVG Volume (30 Days) | ★ 1.6M | 754.5K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | $49,590,000.00 | ★ $82,050,000.00 |
| Revenue This Year | $34.37 | $8.02 |
| Revenue Next Year | $22.86 | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 142.67 | 62.18 |
| 52 Week Low | $5.25 | $38.91 |
| 52 Week High | $10.08 | $147.03 |
| Indicator | XERS | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 59.95 | 57.94 |
| Support Level | $6.98 | $52.37 |
| Resistance Level | $9.01 | $59.40 |
| Average True Range (ATR) | 0.35 | 2.22 |
| MACD | 0.03 | -0.25 |
| Stochastic Oscillator | 94.66 | 50.01 |
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.